France is entering a new era of pharmacy communication.

For decades, French pharmacies operated under strict professional advertising rules that significantly limited their ability to promote their services and communicate with the public.

A decree adopted on 3 March 2026, which came into force on 6 March, has modernised these rules, creating new opportunities for pharmacies to communicate about their activities, expertise and services, while remaining subject to professional and ethical obligations.

For international pharmaceutical companies operating in France — or considering entering the French market — this development deserves particular attention.

It comes at a time when the role of French community pharmacists is expanding beyond the traditional dispensing of medicines. Pharmacists are increasingly involved in vaccination, screening, prevention, medication reviews and the management of chronic conditions.

Yet patients are not always fully aware of the services available at their local pharmacy.

This creates an opportunity for pharmaceutical companies to support pharmacies in making their expertise and services more visible, accessible and understandable.

The strategic challenge is not simply to promote products. It is to become a trusted partner in the transformation of community pharmacy in France.

For international companies, success requires a clear understanding of the French pharmacy ecosystem, its regulatory framework and the importance of professional credibility.

Understanding the role of community pharmacies

Community pharmacies occupy a distinctive position in the French healthcare system.

They are not simply retail outlets for medicines. They are regulated healthcare establishments operated under the professional responsibility of pharmacists, who play an important role in ensuring safe access to medicines and providing healthcare advice.

Their extensive territorial presence makes them among the most accessible points of contact within the French healthcare system.

Over recent years, their responsibilities have expanded to include a broader range of preventive and patient-support services.

These developments are reshaping relationships between pharmacies, patients, healthcare authorities and pharmaceutical companies.

For international laboratories, understanding this transformation is essential.

A successful pharmacy engagement strategy must address not only commercial distribution but also the professional priorities and healthcare responsibilities of pharmacists.

Why are pharmacy groups important in France?

Another distinctive feature of the French market is the role played by groupements de pharmacies, or pharmacy groups and networks.

These organisations bring together independently operated pharmacies around shared services, purchasing arrangements, professional support or common commercial identities.

Their business models vary considerably.

Some focus primarily on improving operational efficiency and purchasing conditions. Others develop strong consumer-facing brands, healthcare services, prevention programmes or digital tools.

For international pharmaceutical companies, these networks can provide valuable opportunities to engage with pharmacists at scale.

However, pharmacy groups should not be approached as interchangeable distribution channels.

Each has its own positioning, priorities and expectations.

An effective partnership therefore begins with an understanding of what the network is trying to achieve for its member pharmacies and their patients.

The decree of 3 March 2026 modernised the professional rules governing communication by French pharmacists.

It expanded the opportunities for pharmacies to communicate about their professional activities and services, including through digital channels.

It also removed previous restrictions that prevented pharmacy groups from promoting their member pharmacies.

For pharmacy networks, this creates new possibilities to develop a more coherent identity and support their members’ visibility.

For pharmaceutical companies, it opens the door to new forms of collaboration centred on patient information, healthcare services and professional expertise.

However, an essential distinction must be made.

Greater freedom for pharmacies to communicate does not mean that pharmaceutical companies can advertise medicines without restriction.

French and European rules governing medicinal product advertising continue to apply, alongside pharmacists’ professional and ethical obligations.

The regulatory treatment of a communication initiative will depend on its content, purpose, audience, product category and distribution channels.

Companies must therefore distinguish between:

• General healthcare and disease-awareness information.
• Communication about services genuinely provided by a pharmacy.
• Institutional communication by a pharmaceutical company.
• Advertising for medicinal products or other regulated healthcare products.

These activities may be subject to different requirements.

Any communication programme involving pharmacies should be reviewed by the relevant medical, legal and regulatory teams before implementation.

The opportunities created by the reform extend beyond marketing.

For international laboratories, pharmacy communication can support three strategic objectives.

Strengthening relationships with pharmacists

Pharmacists face growing expectations from patients while managing increasingly complex professional responsibilities.

They need practical tools to explain healthcare services, provide reliable information and respond to common questions.

Pharmaceutical companies can contribute scientific knowledge, educational resources and communication expertise to support these needs.

A company that provides genuinely useful tools may strengthen its reputation as a professional partner rather than being perceived solely as a product supplier.

Building credibility in the French healthcare ecosystem

France has a demanding healthcare environment in which professional legitimacy, scientific rigour and regulatory compliance are essential.

International companies need to establish credibility with healthcare professionals and demonstrate that they understand local priorities.

Supporting relevant, evidence-based patient information programmes can contribute to this process.

However, credibility cannot be achieved through visibility alone.

It depends on the quality of the information provided, transparency about the company’s involvement and respect for pharmacists’ professional independence.

Developing a distinctive market position

Pharmaceutical companies often compete for the attention of the same pharmacy networks and healthcare professionals.

Providing additional services and practical support can help differentiate their approach.

A carefully designed communication programme can demonstrate that a company understands the challenges faced by French pharmacies and is prepared to invest in long-term professional relationships.

The objective should be to create measurable value for pharmacies and patients, rather than simply increasing the volume of promotional materials distributed.

One practical opportunity is the development of communication toolkits designed specifically for French community pharmacies.

These programmes can help pharmacists explain healthcare topics and make appropriate services more understandable.

However, a successful toolkit should never begin with the question: « What messages does the company want pharmacies to distribute? »

It should begin with a different question:

« What information do pharmacists and patients actually need? »

What should a pharmacy communication toolkit include?

Depending on its objectives and regulatory classification, a programme might include:

Patient education materials

Clear, accessible information about prevention, healthcare conditions, appropriate use of medicines or questions frequently raised by patients.

Digital communication resources

Educational website content and social media materials that pharmacies can adapt to their own communication channels, subject to the applicable approval process.

Practical service information

Materials explaining which healthcare services may be available at a pharmacy, who can access them and how patients can obtain further information.

Training resources for pharmacy teams

Short guides, frequently asked questions and practical explanations to help pharmacists and their staff communicate consistently.

Local communication templates

Adaptable materials allowing pharmacies to communicate accurately about services they actually provide, rather than promoting services that are unavailable at a particular location.

Evaluation tools

Simple mechanisms for collecting pharmacists’ feedback and assessing whether the programme improves the clarity and usefulness of patient information.

The guiding principle should be simplicity.

Pharmacists have limited time. Communication resources must be easy to understand, easy to use and compatible with everyday pharmacy operations.

An illustrative example: a prevention communication programme

Consider an international pharmaceutical company with recognised scientific expertise in a particular area of preventive healthcare.

The company could explore developing an educational programme with a French pharmacy network.

The programme might begin with interviews involving pharmacists to identify patients’ most frequent questions.

Based on these findings, the partners could develop evidence-based educational materials, practical explanations and approved communication templates.

A limited number of pharmacies could test the resources before a wider rollout.

The objective would be to improve access to reliable information and make relevant pharmacy services more understandable.

The company’s role, funding and scientific contribution would need to be transparent, with appropriate safeguards to avoid turning an educational initiative into inappropriate product promotion.

One of the most common mistakes in healthcare communication is developing materials centrally without sufficiently considering how they will be used.

A programme may be scientifically accurate and visually attractive yet fail because it does not reflect everyday pharmacy practice.

Pharmacists understand the questions patients ask, the misunderstandings they encounter and the practical constraints of providing advice at the counter.

This knowledge should inform the programme from the outset.

The value of pharmacist advisory groups

A small advisory group of pharmacists can help international companies identify:

• The information patients find most difficult to understand.
• The healthcare services that remain insufficiently known.
• The formats most likely to be used in pharmacies.
• The practical barriers to implementing a programme.
• The differences between pharmacies serving different populations and territories.

This consultation can also help identify whether communication is genuinely the right solution.

If a service is unavailable, understaffed or difficult to access, a communication campaign alone will not resolve the underlying problem.

The strongest programmes combine scientific expertise with a realistic understanding of pharmacy practice.

Pharmacy groups can provide an effective framework for developing and testing communication initiatives.

They can facilitate access to participating pharmacies, coordinate feedback and support the distribution of approved materials.

But the partnership needs to be structured carefully.

A practical approach involves four stages.

Stage 1 — Identify a shared healthcare priority

The programme should address a topic that matters to patients, pharmacists and the participating network.

Stage 2 — Define each partner’s responsibilities

The laboratory may contribute scientific expertise, educational resources or funding. The pharmacy group may coordinate participating pharmacies and support implementation. Each pharmacist retains their professional responsibilities.

Stage 3 — Test the programme in a limited number of pharmacies

A pilot makes it possible to evaluate whether the materials are useful and manageable before investing in wider deployment.

Stage 4 — Measure results and adapt

Feedback should inform improvements to content, training and delivery.

The partnership should also establish clear rules concerning content ownership, scientific validation, regulatory approvals, funding transparency and communication responsibilities.

For foreign companies unfamiliar with the French market, a local communications partner can help facilitate these discussions and translate strategic objectives into practical programmes.

Communication with pharmacies is only one dimension of building a reputation in France.

International pharmaceutical companies also need to establish their visibility and credibility within the wider healthcare ecosystem.

This is where media relations can play a strategic role.

France has a diverse media landscape, including national newspapers, business publications, specialist healthcare media, pharmaceutical trade publications, regional newspapers and broadcast media.

Each addresses different audiences and requires a tailored editorial approach.

A company entering the French market cannot assume that its international reputation will automatically translate into recognition among French stakeholders.

It needs to explain its activities, demonstrate its expertise and establish relationships with journalists who cover the relevant healthcare issues.

What makes a pharmaceutical company relevant to French journalists?

Journalists are generally more interested in the broader significance of a development than in a company’s commercial objectives.

Potentially relevant topics include:

• Changes in healthcare needs and patient expectations.
• New approaches to prevention and patient support.
• Research findings with meaningful implications for public health.
• Insights into the evolving role of community pharmacists.
• Healthcare initiatives responding to specific regional challenges.
• Evidence-based findings from programmes implemented with healthcare professionals.

For example, a properly designed study exploring pharmacists’ experience of patients’ prevention needs could provide useful insights for healthcare journalists.

A programme developed with pharmacy networks might also generate lessons about how patients access healthcare information.

However, media coverage should not be treated as an automatic outcome. A story needs genuine editorial relevance, reliable evidence and credible spokespersons.

Why is local media knowledge essential?

The French media environment is highly segmented.

National publications may focus on healthcare policy, industry developments or public health issues.

Specialist media may examine the practical implications for pharmacists, healthcare professionals and pharmaceutical companies.

Regional media may be interested in how a programme affects access to healthcare in a particular territory.

An effective strategy therefore requires both a national perspective and detailed knowledge of specialist and regional outlets.

For international laboratories, local media expertise can help avoid generic communication campaigns that fail to resonate with French audiences.

Reputation is built through consistent actions rather than isolated communication campaigns.

For international laboratories, several principles are particularly important.

Demonstrate scientific credibility

Communication should be based on robust evidence, with clear explanations of what is known, what remains uncertain and what conclusions can reasonably be drawn.

Understand French healthcare priorities

Messages developed for other markets may not address the concerns of French pharmacists, patients or healthcare stakeholders.

Local adaptation should go beyond translation.

Be transparent about partnerships

When a laboratory contributes to an initiative involving pharmacies, its role should be clearly identified.

Educational programmes should not conceal commercial objectives or create confusion about the independence of healthcare professionals.

Prioritise long-term relationships

Building credibility among pharmacy groups, healthcare professionals and journalists requires sustained engagement.

A single campaign may generate attention, but a consistent programme of useful information and credible initiatives is more likely to support lasting recognition.

Prepare for sensitive questions

Pharmaceutical companies operate in a highly scrutinised environment.

They should anticipate questions about scientific evidence, funding, commercial interests, patient protection and regulatory compliance.

Clear governance and well-prepared spokespersons are essential.

International pharmaceutical companies do not need to launch a nationwide programme immediately.

A structured 100-day pilot can provide a practical starting point.

Days 1–15: understand before communicating

Assess the relevant pharmacy networks, existing communication practices, patient information needs and regulatory constraints.

Identify one clearly defined opportunity rather than attempting to address every pharmacy service simultaneously.

Days 16–30: involve pharmacists

Consult a small group of pharmacists to test assumptions and understand the practical challenges.

Clarify the contribution expected from the laboratory and any participating pharmacy group.

Days 31–45: develop a credible communication proposition

Define the audience, the problem being addressed, the intended messages and the evidence supporting them.

Prepare materials for scientific and regulatory review.

Days 46–60: launch a targeted pilot

Introduce the approved programme to participating pharmacies.

Ensure pharmacy teams understand the content and can respond to patient questions.

Days 61–80: learn from real-world implementation

Monitor whether materials are used, whether patients understand them and whether pharmacists consider them helpful.

Adapt the programme where necessary.

Days 81–100: evaluate before scaling

Assess the results against the original objectives.

Decide whether to continue, modify, expand or discontinue the programme.

The 100-day framework is an indicative project-management roadmap, not a guarantee that all regulatory approvals or partnership negotiations can be completed within that period.

The success of a pharmacy communication programme should not be measured solely by the number of toolkits distributed or social media impressions generated.

A more meaningful evaluation considers several dimensions.

Pharmacist engagement: Are participating pharmacies actually using the resources?

Patient understanding: Do the materials help patients better understand the information or services presented?

Practical usefulness: Does the programme support pharmacy teams without creating excessive additional work?

Communication reach: Are the relevant audiences accessing the content?

Reputation: Does the initiative contribute to stronger recognition of the laboratory as a credible and useful partner?

Compliance: Have the necessary approvals, disclosures and controls been implemented effectively?

Commercial outcomes, where relevant and lawful to assess, should be analysed separately from patient education and public health objectives.

A successful pilot should generate reliable insights that can guide future decisions, rather than promise an immediate commercial return.

Entering a new market involves more than translating existing materials.

International pharmaceutical companies must understand local expectations, identify the right stakeholders and adapt their communication to the French healthcare environment.

A French communications agency can help connect these different dimensions.

Its contribution may include understanding the local media landscape, identifying relevant pharmacy networks, translating complex scientific information into accessible messages, developing communication strategies and supporting the rollout of programmes.

For foreign laboratories, this combination of strategic advice and local execution can help bridge the gap between international objectives and French market realities.

The most effective approach is collaborative, involving the laboratory’s medical, legal and regulatory teams alongside pharmacists and other relevant partners.

France’s March 2026 pharmacy communication reform creates opportunities for community pharmacies to become more visible and better explain their expanding healthcare role.

For international pharmaceutical companies, it also provides an opportunity to rethink how they engage with the French pharmacy ecosystem.

The companies best positioned to benefit will not necessarily be those producing the greatest volume of promotional materials.

They will be those capable of understanding pharmacists’ needs, supporting reliable patient information and building transparent, long-term professional relationships.

In France, building a successful pharmaceutical presence requires more than market access. It requires trust, credibility and a deep understanding of the local healthcare ecosystem.

How Agence Constance supports international pharmaceutical companies in France

Agence Constance is a French strategic communications and media relations consultancy helping companies build their visibility, reputation and credibility in the French market.

We combine strategic advice, corporate communications, media relations and content development with an in-depth understanding of the French media landscape.

Our experience includes working with major national media such as TF1, France 2, France Inter, Le Monde, Les Échos, Le Figaro, France 24, RFI and BFM, alongside specialist, sector-specific and regional publications.

For international pharmaceutical companies, we can help:

• Assess their visibility and reputation in the French market.
• Identify relevant stakeholders and communication opportunities within the pharmacy ecosystem.
• Develop clear, credible positioning and key messages.
• Design educational communication programmes and pharmacy toolkits, working alongside medical and regulatory teams.
• Build relationships with French national, healthcare, pharmaceutical trade and regional media.
• Prepare executives and scientific experts for media engagement.
• Test communication initiatives through targeted pilot programmes and evaluate their results.

Our recommended first step: a French Pharmacy Communication & Reputation Assessment.

This initial assessment identifies the company’s visibility challenges, relevant pharmacy stakeholders, priority communication opportunities and the conditions for a targeted pilot programme.

It provides a practical foundation for developing a communication strategy tailored to the French market.

Planning to enter or expand in the French pharmaceutical market? Contact Agence Constance to discuss your communication and reputation strategy.